Ketamine clinical trials in the registry
Data as of 10 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
Ketamine is a medicine long used in anaesthesia that is also studied in psychiatry. Most ketamine records in the registry concern anaesthesia, sedation or pain, so this page counts those separately and lists only studies classified as psychiatric research.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 458 registered Ketamine studies are counted on this page (psychiatric research only).
Psychiatric research and anaesthesia or pain research
Registry records tagged ketamine are mostly anaesthesia, sedation and pain studies. PsychoactiveMap sorts them with keyword rules applied to each title and summary. This page lists and counts only the psychiatric group; the other groups are counted here and left out of every figure below. The rules can misplace a record, so check the registry entry.
| Group | Studies | On this page |
|---|---|---|
| Psychiatric research | 463 | Listed and counted |
| Anaesthesia, sedation and pain | 1,225 | Counted here only |
| Not classified | 96 | Counted here only |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 80 | 17% |
| Not yet recruiting | 24 | 5% |
| Enrolling by invitation | 7 | 2% |
| Active, not recruiting | 17 | 4% |
| Completed | 201 | 44% |
| Terminated | 38 | 8% |
| Suspended | 4 | 1% |
| Withdrawn | 26 | 6% |
| Status not reported | 61 | 13% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Early Phase 1 | 26 | 6% |
| Phase 1 | 76 | 17% |
| Phase 2 | 131 | 29% |
| Phase 3 | 48 | 10% |
| Phase 4 | 65 | 14% |
| Not applicable | 65 | 14% |
| Not reported | 47 | 10% |
Countries
Country is taken from the study's linked research site. 13 of 458 records have no country on file. The top 10 countries are shown.
| Country | Studies | Share |
|---|---|---|
| United States | 269 | 59% |
| Canada | 36 | 8% |
| China | 17 | 4% |
| France | 14 | 3% |
| United Kingdom | 11 | 2% |
| Israel | 10 | 2% |
| Austria | 9 | 2% |
| Brazil | 7 | 2% |
| Australia | 6 | 1% |
| Germany | 6 | 1% |
When studies started
| Start year | Studies |
|---|---|
| 2024 to 2026 | 114 |
| 2020 to 2023 | 129 |
| 2015 to 2019 | 127 |
| 2010 to 2014 | 70 |
| Before 2010 | 17 |
| Start date not reported | 1 |
Study design
- 411 interventional and 46 observational studies.
- Median planned or actual enrolment is 41 participants (range 1 to 50,000, across 433 records that report it).
Topics named in study titles
A keyword match on registered titles, so one study can appear under more than one topic and a study can be missed. It describes what titles mention, nothing more.
| Topic | Studies |
|---|---|
| Depression and mood | 245 |
| Suicidal thoughts | 64 |
| Trauma and PTSD | 23 |
| Other substance use | 15 |
| Alcohol use | 14 |
| Pain and headache | 14 |
| Cancer and end of life | 12 |
| Obsessive-compulsive disorder | 11 |
Most recently started studies
The 25 studies with the latest start dates, shown newest first. The order is not a ranking and says nothing about quality. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Registry ID | Title as registered | Status | Phase | Country | Start |
|---|---|---|---|---|---|
| NCT07768618 | Electrophysiologic Mechanisms of Ketamine Antidepressant Response | Not yet recruiting | Phase 2 | United States | 2026-12 |
| NCT07683988 | Oral and Sublingual Ketamine | Not yet recruiting | Phase 1 | Canada | 2026-10 |
| NCT07839338 | A Study Comparing Oral Ketamine With Oral Midazolam for the Treatment of Major Depressive Episodes | Not yet recruiting | Phase 3 | India | 2026-10 |
| NCT07868913 | Alleviating Suicidality by Combining Psychotherapy and IM Ketamine for Rapid Treatment in the Emergency Department | Recruiting | Phase 2 | United States | 2026-09 |
| NCT07810023 | Intramuscular Ketamine for Suicidal Patients in the Evanston Hospital Emergency Department for Suicidal Distress | Enrolling by invitation | Not applicable | United States | 2026-09 |
| NCT07801703 | Behavioural Activation Therapy and Ketamine for Treatment-Resistant Depression | Not yet recruiting | Phase 2 | Canada | 2026-09 |
| NCT07824973 | Ketamine Treatment for Treatment-Resistant Depression - the Role of Framing | Not yet recruiting | Not applicable | Sweden | 2026-09 |
| NCT07760740 | The Effect of Intraoperative Infusion of Esketamine on Cholestatic Pruritus in Patients Undergoing Hepatobiliary Surgery | Not yet recruiting | Not applicable | China | 2026-08 |
| NCT07716098 | A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression | Recruiting | Phase 3 | Taiwan | 2026-08 |
| NCT07614581 | Intra-Sessional Autonomic Arc Detection in Ketamine-Assisted Therapy for PTSD: A Signal Characterisation Pilot Study | Not yet recruiting | Not reported | Canada | 2026-07 |
| NCT07680140 | Biomarker-Guided Antidepressant Selection | Recruiting | Phase 4 | United States | 2026-07 |
| NCT07723066 | Biomarker Discovery for Suicide Precision Circuit Therapeutics | Not yet recruiting | Not reported | United States | 2026-07 |
| NCT07569198 | Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT) | Recruiting | Phase 2 | Canada | 2026-06 |
| NCT07602153 | Multimodal Pharmacological Study of Clinical Cohorts for Major Depressive Disorder | Not yet recruiting | Not reported | Not reported | 2026-05 |
| NCT07639359 | Subanesthetic Ketamine Infusions for Depressive Symptoms in Intensive Care Unit Patients | Recruiting | Phase 2 | United States | 2026-05 |
| NCT06781697 | InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression | Recruiting | Phase 3 | Canada | 2026-05 |
| NCT06835504 | Morphine or Ketamine for Analgesia | Not yet recruiting | Phase 3 | United States | 2026-05 |
| NCT07563296 | KALM-B: Ketamine-assisted Psychotherapy (KAP) to Lessen Morbidity After Burn Injury | Recruiting | Phase 2 | United States | 2026-04 |
| NCT07563868 | Coaching as an Adjunct to Ketamine Therapy for Treatment-Resistant Depression | Recruiting | Not applicable | United States | 2026-04 |
| NCT07528014 | ATLAS-1: Advanced Trial for Longitudinal Assessment in Salma 1 | Recruiting | Not reported | United States | 2026-03 |
| NCT07462559 | KF2025#1 Trial: Ketamine, Cannabidiol and Cobicistat Interaction Study | Not yet recruiting | Phase 1 | Finland | 2026-03 |
| NCT06378528 | Ketamine-assisted Psychotherapy for Adolescent PTSD (KAP) | Suspended | Early Phase 1 | United States | 2026-03 |
| NCT07396272 | A Clinical Trial of Add-on Oral Slow-release Ketamine Treatment in Major Depression | Active, not recruiting | Phase 2 | Sweden | 2026-03 |
| NCT06788249 | Pilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of Ketamine | Recruiting | Early Phase 1 | United States | 2026-02 |
| NCT07139106 | Understanding the Role of the Kappa Opioid Receptor in Ketamine's Attenuation of Suicidal Thoughts | Not yet recruiting | Phase 4 | United States | 2026-02 |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals.
Other substance hubs
Psilocybin | MDMA | LSD | DMT | 5-MeO-DMT | Ayahuasca | Ibogaine
Registry status hubs
Recruiting | Not yet recruiting | Active, not recruiting | Enrolling by invitation | Completed | Terminated | Suspended | Withdrawn
Phase hubs
Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Phase not applicable